Drug Companies' Patient-Assistance Programs — Helping Patients or Profits?

Abstract

Pharmaceutical manufacturers have attempted to blunt the impact of drug copayments and coinsurance on patients by funding patient-assistance programs. But these programs may lead to higher drug prices, undermining the beneficial aspects of cost sharing.